Peptomyc is a clinical-stage biotech spin‑out developing cell‑penetrating mini‑protein therapeutics that directly inhibit the MYC oncoprotein, with a lead candidate (OMO‑103) that has completed Phase I and is advancing in Phase Ib/II studies for multiple solid tumors[1][3].
High-Level Overview
- Mission: Peptomyc’s stated mission is to develop foundational therapies that inhibit MYC activity to improve survival and quality of life for cancer patients with abnormal MYC signalling[1].
- Investment philosophy / (not applicable): Peptomyc is a biotech company (spin‑out), not an investment firm; its funding history includes seed and series A rounds and non‑dilutive awards such as Horizon Europe / EIC and national grants to support clinical and manufacturing development[4][7][5].
- Key sectors: Oncology therapeutics, specifically targeted biologics/mini‑proteins and cell‑penetrating peptide (CPP) technology aimed at oncogenic transcription factor inhibition[1][2].
- Impact on the startup / scientific ecosystem: Peptomyc is notable as a spin‑out from Vall d’Hebron Institute of Oncology (VHIO) and ICREA that translated long‑standing academic work on Omomyc into a first‑in‑class therapeutic candidate; it represents a rare example of a direct MYC inhibitor reaching human trials, potentially enabling a new drug modality for broadly applicable cancer targets[1][3][4].
For the product/company focus in two short paragraphs:
Peptomyc builds cell‑penetrating mini‑protein therapeutics derived from the Omomyc mini‑protein to directly inhibit the MYC transcription factor, a central driver of cancer proliferation, survival, and therapy resistance[1][3]. The lead asset, OMO‑103, is presented as a first‑in‑class direct MYC inhibitor that has completed Phase I and is being tested in combination and disease‑specific trials (e.g., pancreatic cancer, osteosarcoma) while the company scales manufacturing and develops companion diagnostics[3][6][7].
Peptomyc’s approach targets a broad patient population across tumor types characterized by abnormal MYC activity rather than mutation‑specific subgroups, positioning the therapy as potentially applicable across many cancers where MYC is dysregulated[4][1].
2. Origin Story
- Founding year and institutional roots: Peptomyc was founded in December 2014 as a spin‑off from the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institution for Research and Advanced Studies (ICREA)[2][5].
- Founders and backgrounds: The company was founded by Dr. Laura Soucek (the MYC field leader who designed Omomyc) and Dr. Marie‑Eve Beaulieu (protein scientist who discovered Omomyc’s cell‑penetrating properties), together with VHIO and ICREA as institutional co‑founders[1][3].
- How the idea emerged: The therapeutic idea grew from >20 years of preclinical research demonstrating that Omomyc can inhibit MYC activity and, crucially, that modified mini‑proteins could penetrate cells and reach nuclear MYC targets—work that shifted the concept from academic proof‑of‑principle to a drug development program[4][1].
- Early traction / pivotal moments: Key milestones include successful preclinical efficacy, seed and Series A financing (including early public and private support), the first‑in‑human Phase I with a direct MYC inhibitor, and recent non‑dilutive awards (EIC/Horizon Europe, Spanish Ministry grants) to support clinical expansion, manufacturing scale‑up, and companion diagnostic development[4][3][7][5].
Core Differentiators
- First‑in‑class direct MYC inhibition: Peptomyc’s leading claim is being the first company to take a direct MYC inhibitor (Omomyc‑derived mini‑protein / OMO‑103) into human trials, addressing a historically “undruggable” oncogenic transcription factor[3][1].
- Mini‑protein / CPP modality: The technology uses cell‑penetrating mini‑proteins (CPPs) that can enter cells and interfere with nuclear MYC function—offering a different modality from small molecules, antibodies, or conventional biologics[1][2].
- Broad applicability: Because MYC is a central driver in many cancers, the approach targets a wide range of tumor types rather than a narrow mutation subset, which could enable a “pan‑tumor” application if efficacy and safety are confirmed[4][1].
- Academic pedigree and translational track record: The company originates from leading translational labs (VHIO/ICREA) with founders who are field experts, which aided progression from bench to clinic[1][3].
- Clinical progress and funding: Completed Phase I, ongoing Phase Ib/II studies in multiple indications, and material grants (EIC/Horizon, Spanish Ministry) support clinical and CMC (chemistry, manufacturing, controls) development—reducing some execution risk compared with earlier preclinical ventures[3][7][5].
Role in the Broader Tech and Therapeutics Landscape
- Trend alignment: Peptomyc rides two major trends: a shift toward biologics and engineered peptides/proteins as precision therapeutics, and growing efforts to drug transcription factors that were previously labelled “undruggable.” The company’s mini‑protein CPP approach exemplifies that evolution[1][2].
- Timing and market forces: Advances in peptide/protein design, delivery technologies, and increased tolerance for novel modalities in oncology clinical development have made translation of Omomyc feasible now; additionally, the large unmet need and commercial market for broadly active oncology agents favors a successful pan‑tumor MYC inhibitor[4][1].
- Influence on ecosystem: If OMO‑103 demonstrates meaningful efficacy with acceptable safety, Peptomyc could validate MYC as a therapeutic node and catalyze new investment and research into mini‑proteins and CPP‑based oncology drugs, influencing both academic programs and biopharma pipelines[3][4].
- Challenges and headwinds: Typical biotech risks apply—clinical efficacy, safety, manufacturing scale‑up for protein therapeutics, and the challenge of identifying patients most likely to benefit (necessitating companion diagnostics) remain material execution points[7][5].
Quick Take & Future Outlook
- What’s next: Near‑term priorities for Peptomyc are advancing OMO‑103 in combination trials (e.g., with gemcitabine/nab‑paclitaxel in metastatic pancreatic cancer), progressing disease‑specific studies (Phase II in osteosarcoma among others), developing companion diagnostics, and scaling manufacturing capacity[7][6][3].
- Trends that will shape the journey: Outcomes of ongoing clinical trials, performance of the companion diagnostic strategy, improvements in protein delivery/manufacturing, and competitive progress in MYC or transcription‑factor targeting from other groups will determine strategic options and partnering/exit timing[7][1].
- How influence might evolve: A positive clinical readout could reposition MYC from a theoretical target to a validated clinical target, attracting partnerships and broader application across tumor types; conversely, negative safety/efficacy signals would underscore the difficulty of translating transcription factor inhibition and could slow similar ventures[3][4].
Quick take: Peptomyc is one of the most noteworthy anti‑MYC translation efforts—a small, academically rooted biotech that has already crossed the key milestone of human dosing with a first‑in‑class mini‑protein inhibitor and is now executing on combination and disease‑specific trials while scaling manufacturing and diagnostic capabilities[3][1]. Its success would be paradigm‑shifting for oncology; its near‑term fate depends on forthcoming clinical data and the company’s ability to industrialize a novel biologic modality[7][5].
